Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$1.02 USD
-0.03 (-2.39%)
Updated Sep 19, 2024 03:56 PM ET
After-Market: $1.01 -0.01 (-0.98%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth C Momentum C VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 34% (85 out of 251)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.00 | 1.38 | 9.99 |
Current Quarter Estimate | -0.54 | 3.11 | 61.00 |
Year Ago Quarter Estimate | -7.35 | -4.81 | 54.84 |
Next Quarter Estimate | -0.40 | 3.91 | 63.00 |
Next Year Estimate | -1.56 | 24.92 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 91.44 | 17.30 | 15.67 |
Next Year | 31.88 | 9.50 | 11.34 |
Last 5 Years | NA | 0.90 | 8.10 |
Next 5 Years | NA | 22.10 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -6.90 |
Price/Book (MRQ) | 1.49 | 2.10 |
Price/Cash Flow (MRFY) | NA | 16.43 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -21,963.75% | -150.51% |
Return on Equity (TTM) | -1,901.11% | -61.16% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.